Description

4-Amino-1-tert-Butyl-3-(3-Methylbenzyl)Pyrazolo[3,4-D]Pyrimidine is a high-purity, advanced pharmaceutical intermediate belonging to the pyrazolopyrimidine class of heterocyclic compounds. This compound is a critical building block in the synthesis of targeted kinase inhibitors, offering significant value in modern drug discovery and development pipelines. It is primarily required by pharmaceutical R&D laboratories and fine chemical manufacturers engaged in producing innovative therapeutics for oncology and inflammatory diseases.

Application

• Pharmaceutical Intermediate: A key precursor in the synthesis of potent and selective protein kinase inhibitors.
• Oncology Research: Used in the development of novel anti-cancer drugs targeting specific signaling pathways.
• Inflammatory Disease Therapeutics: Serves as a core scaffold for compounds aimed at treating autoimmune and chronic inflammatory conditions.
• Biochemical Research: Employed as a reference standard or tool compound in enzymatic assays and target validation studies.
• Custom Synthesis: Utilized by contract research and manufacturing organizations (CROs/CMOs) for client-specific drug development projects.
• Academic Research: Facilitates medicinal chemistry and pharmacology studies in university and institutional laboratories.

Basic Information

Product Name	4-Amino-1-tert-Butyl-3-(3-Methylbenzyl)Pyrazolo[3,4-D]Pyrimidine
CAS No.	956025-83-5
Molecular Formula	C18H23N5
Molecular Weight	309.41 g/mol
Synonyms	4-Amino-1-(tert-butyl)-3-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidine; 1H-Pyrazolo[3,4-d]pyrimidine, 4-amino-1-(1,1-dimethylethyl)-3-[(3-methylphenyl)methyl]-; 4-Amino-1-tert-butyl-3-(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidine; 4-Amino-1-tert-butyl-3-(m-tolylmethyl)pyrazolo[3,4-d]pyrimidine; ABT-869 Intermediate; Linifanib Intermediate; 956025-83-5
EINECS	Contact for details

Quality Control

Our production of 4-Amino-1-tert-Butyl-3-(3-Methylbenzyl)Pyrazolo[3,4-D]Pyrimidine adheres to stringent quality management systems, ensuring batch-to-batch consistency and high purity suitable for pharmaceutical applications. All material is accompanied by a comprehensive Certificate of Analysis (COA) detailing purity, identity, and impurity profiles as determined by advanced analytical techniques including HPLC, NMR, and MS. We support compliance with cGMP and ICH Q7 guidelines for active pharmaceutical ingredients (APIs) and advanced intermediates.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at controlled room temperature (15-25°C). Keep the container tightly sealed in a dry environment to protect the compound from moisture. Store away from incompatible materials.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (HPLC)	Conforms
Identification (IR)	Conforms
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm
Single Unknown Impurity (HPLC)	≤ 0.5%
Total Impurities (HPLC)	≤ 2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.